AR030630A1 - Composiciones farmaceuticas - Google Patents

Composiciones farmaceuticas

Info

Publication number
AR030630A1
AR030630A1 ARP010104260A ARP010104260A AR030630A1 AR 030630 A1 AR030630 A1 AR 030630A1 AR P010104260 A ARP010104260 A AR P010104260A AR P010104260 A ARP010104260 A AR P010104260A AR 030630 A1 AR030630 A1 AR 030630A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
disorder
composition
treatment
condition
Prior art date
Application number
ARP010104260A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR030630A1 publication Critical patent/AR030630A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

Una composicion para el tratamiento de un desorden o condicion dependiente de la ciclo-oxigenasa-2, la cual comprende: ácido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacético o una sal farmacéuticamente aceptable del mismo, cuya composicion es una composicion farmacéutica de liberacion inmediata para el tratamiento de dicho desorden o condicion durante aproximadamente 24 horas.
ARP010104260A 2000-09-11 2001-09-07 Composiciones farmaceuticas AR030630A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23165500P 2000-09-11 2000-09-11
US23226100P 2000-09-14 2000-09-14

Publications (1)

Publication Number Publication Date
AR030630A1 true AR030630A1 (es) 2003-08-27

Family

ID=26925315

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104260A AR030630A1 (es) 2000-09-11 2001-09-07 Composiciones farmaceuticas

Country Status (28)

Country Link
US (2) US20020061932A1 (es)
EP (1) EP1331972B1 (es)
JP (2) JP2004527458A (es)
KR (1) KR20030036730A (es)
CN (1) CN100490797C (es)
AR (1) AR030630A1 (es)
AT (1) ATE366128T1 (es)
AU (2) AU1390002A (es)
BR (1) BR0113809A (es)
CA (1) CA2416771C (es)
CY (1) CY1107729T1 (es)
CZ (1) CZ2003673A3 (es)
DE (1) DE60129238T2 (es)
DK (1) DK1331972T3 (es)
ES (1) ES2290181T3 (es)
HU (1) HUP0301128A3 (es)
IL (2) IL154238A0 (es)
MX (1) MXPA03002105A (es)
MY (1) MY126117A (es)
NO (1) NO20031095L (es)
NZ (1) NZ524785A (es)
PE (1) PE20020351A1 (es)
PL (1) PL359721A1 (es)
PT (1) PT1331972E (es)
RU (1) RU2316324C2 (es)
SI (1) SI1331972T1 (es)
SK (1) SK2902003A3 (es)
WO (1) WO2002020090A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114527A1 (en) * 2001-08-31 2003-06-19 Karnachi Anees Abdulquadar Pharmaceutical composition
GB0201520D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Pharmaceutical uses
CN1330300C (zh) * 2002-03-07 2007-08-08 诺瓦提斯公司 药物组合物
AU2003248642A1 (en) 2002-06-11 2003-12-22 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
PE20040844A1 (es) 2002-11-26 2004-12-30 Novartis Ag Acidos fenilaceticos y derivados como inhibidores de la cox-2
TWI327913B (en) * 2003-03-12 2010-08-01 Novartis Ag Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
FR2898492B1 (fr) * 2006-03-15 2008-06-06 Pierre Fabre Medicament Sa Comprimes orodispersibles de domperidone
US20080014228A1 (en) * 2006-07-14 2008-01-17 Olivia Darmuzey Solid form
US20080237823A1 (en) * 2007-01-11 2008-10-02 Analog Devices, Inc. Aluminum Based Bonding of Semiconductor Wafers
US20110144206A1 (en) * 2008-08-22 2011-06-16 Steven Lewitzky Use of a cox-2 inhibitor for the treatment of a cox-2 dependent disorder in a patient not carrying hla alleles associated with hepatotoxicity
US8227451B2 (en) 2008-11-12 2012-07-24 Auspex Pharmaceuticals Phenylacetic acid inhibitors of cyclooxygenase
CN103773596B (zh) * 2013-12-31 2016-05-18 上海复力生物医药科技有限公司 磷虾油的制备方法
US11730725B2 (en) 2017-09-26 2023-08-22 Tesaro, Inc. Niraparib formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0701449T3 (da) * 1993-06-08 2003-11-10 Novartis Ag Fremgangsmåde til fremstilling af en oral fast dosisform indeholdende diclofenac
WO1997044028A1 (en) * 1996-05-17 1997-11-27 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US20030114527A1 (en) * 2001-08-31 2003-06-19 Karnachi Anees Abdulquadar Pharmaceutical composition

Also Published As

Publication number Publication date
NZ524785A (en) 2005-10-28
MXPA03002105A (es) 2003-06-19
ATE366128T1 (de) 2007-07-15
US20020061932A1 (en) 2002-05-23
PE20020351A1 (es) 2002-06-14
CN1455691A (zh) 2003-11-12
JP2011144194A (ja) 2011-07-28
IL154238A (en) 2008-11-26
CA2416771C (en) 2010-11-02
SK2902003A3 (en) 2003-10-07
US20040186179A1 (en) 2004-09-23
KR20030036730A (ko) 2003-05-09
CN100490797C (zh) 2009-05-27
ES2290181T3 (es) 2008-02-16
BR0113809A (pt) 2003-07-29
CA2416771A1 (en) 2002-03-14
DE60129238D1 (de) 2007-08-16
SI1331972T1 (sl) 2007-12-31
PL359721A1 (en) 2004-09-06
RU2316324C2 (ru) 2008-02-10
AU1390002A (en) 2002-03-22
WO2002020090A9 (en) 2003-10-30
NO20031095D0 (no) 2003-03-10
WO2002020090A3 (en) 2003-05-30
MY126117A (en) 2006-09-29
PT1331972E (pt) 2007-10-16
CZ2003673A3 (cs) 2003-06-18
AU2002213900B2 (en) 2006-02-16
DE60129238T2 (de) 2008-03-06
IL154238A0 (en) 2003-09-17
NO20031095L (no) 2003-03-10
HUP0301128A3 (en) 2005-04-28
EP1331972B1 (en) 2007-07-04
HUP0301128A2 (hu) 2003-10-28
JP2004527458A (ja) 2004-09-09
WO2002020090A2 (en) 2002-03-14
AU2002213900C1 (en) 2006-07-27
EP1331972A2 (en) 2003-08-06
DK1331972T3 (da) 2007-11-05
CY1107729T1 (el) 2013-04-18

Similar Documents

Publication Publication Date Title
AR030630A1 (es) Composiciones farmaceuticas
DK1411900T4 (da) Farmaceutiske sammensætninger til den koordinerede frigørelse af NSAIDs
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
BR0015188A (pt) Composições farmacêuticas
PE20020802A1 (es) COMPUESTO DE LACTAMA COMO INHIBIDOR DE LA LIBERACION DEL PEPTIDO ß-AMILOIDE
AR039164A1 (es) Sales de venlafaxina de baja solubilidad en agua
AR079706A1 (es) Composiciones, metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis y uso
CO5560554A2 (es) Composicion farmaceutica que comprende lumiracoxib
NO20052907D0 (no) Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
AR062659A1 (es) Composicion de liberacion sostenida de levodopa y metodo para su uso
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
BR0005915A (pt) Comprimido matriz que possibilita a liberação prolongada de trimetazidina após a administração pela via oral
DE60336225D1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
CO5190674A1 (es) Tratamiento de desordenes neuroticos desordenes neuroticos
AR014964A1 (es) Derivados de indol, composiciones farmaceuticas que los contienen, agentes para reducir la presion intraocular, tratar glaucoma e hipertension ocular, usosen la fabricacion de composiciones farmaceuticas y procedimiento de fabricacion de dichas composiciones
ATE347358T1 (de) Schwimmende orale formulierungen mit kontrollierter freisetzung von betain
PL360492A1 (en) Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates
BRPI0413478A (pt) solução farmacêutica aquosa compreendendo oximetazolina e/ou xilometazolina
AR029666A1 (es) Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina
ECSP034484A (es) Composiciones farmaceuticas
TW200505429A (en) Pharmaceutical composition
PA8483301A1 (es) Concentrado oral de sertralina
DE60112578D1 (de) Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase
AR038747A1 (es) Una composicion farmaceutica solida para tratar un desorden o condicion dependiente de la ciclooxigenasa-2
EA200500957A1 (ru) Применение l-допа, его производных и лекарственных средств, содержащих эти соединения, для профилактики психотических заболеваний

Legal Events

Date Code Title Description
FB Suspension of granting procedure